CClinicalTrials.gg
CompletedNCT03424928Updated Feb 7, 2018

A Pilot Bioequivalence Study of Pomalidomide

A Phase 1 interventional study of Pomalidomide 4 MG Oral Capsule and Pomalidomide 4 MG Oral Capsule-Pomalyst in Bioequivalence, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-07.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

Pomalidomide capsule were developed to offer an alternative to the marketed formulation, This pilot study was aim to pre-assess the bioequivalence of the capsule formulations under fasted condition.

02

Conditions studied

  • Bioequivalence

Keywords

  • Pomalidomide
  • Multiple myeloma
  • Bioequivalence
03

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subjects should read, sign and date an Informed Consent Form and be fully informed of possible adverse events prior to any study procedures.
  • Subjects should complete the trial according to the regulations.
  • Subjects must agree to take effective contraceptive methods to prevent pregnancy from 2 weeks before screening until 3 months of last dose administration. Subjects must agree to avoid semen and blood donation until 3 months of last dose administration.
  • Healthy male volunteers of 18-50 years old.
  • Body mass index (BMI) ranges from 18.0 to 28.0 kg/m2, body weight ≥ 50 kg.
  • Medically healthy subjects with clinically normal Neutrophils and Platelets within 14 days.
  • No history of heart, liver, kidney, gastrointestinal tract diseases, nervous system, neural abnormities or metabolic abnormalities.

Exclusion criteria

Exclusion Criteria:

  • Smokers (>3 cigarettes/day)
  • History of allergic reactions to pomalidomide or Thalidomide analogues. Any food allergies, which in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study.
  • Any history of thrombus or liver, kidney diseases.
  • History of Alcohol abuse (3990 ml beer, 1400 ml wine, 350 ml spirits/week)
  • Recent donation of plasma or significant loss of whole blood (>400 ml) within 3 months.
  • Subjects have difficulty to swallow or any clinical significant history of ongoing gastrointestinal problems which affect absorption of drugs.
  • Received a prescription medicine within 2 weeks prior to study dosing.
  • Received a non-prescription drugs, traditional Chinese medicine, health products within prior to study dosing.
  • Received a special food (dragon fruit, grapefruit or other tropical fruit) or strenuous exercise within 1 week prior to study dosing. Regular use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to study administration.
  • Any anticipation in other trial within 3 months.
  • Abnormal laboratory tests judged clinically significant.
  • Positive test result for HBsAg, HBeAg, HBeAb, HBcAB, HCvAB, HIV antibody, Syphilis screening antibody.
  • Received a caffeine/Xanthine beverages or food within 48 h prior to study dosing.
  • Received an alcohol within 24 h prior to study dosing or positive test result for alcohol screening.
  • Positive test result for drugs of abuse.
  • Other reasons which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study.
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Pomalidomide 4 MG Oral Capsule

    per os,capsule,4mg,1 capsule per period

    Drug: Pomalidomide 4 MG Oral Capsule

  • Experimental
    Pomalidomide 4 MG Oral Capsule-Pomalyst

    per os,capsule,4mg,1 capsule per period

    Drug: Pomalidomide 4 MG Oral Capsule-Pomalyst

Interventions

  • DrugPomalidomide 4 MG Oral Capsule

    per os,capsule,4mg,1 capsule per period

  • DrugPomalidomide 4 MG Oral Capsule-Pomalyst

    per os,capsule,4mg,1 capsule per period

05

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    90% CI of T/R within 80-125%

    Time frame: Day 1, Day 2, Day 3 of cycle 1, Day 8, Day 9, Day 10 of cycle 2.

  2. Area under the plasma concentration versus time curve from 0 to the last measurable concentration (AUC0-t)

    90% CI of T/R within 80-125%

    Time frame: Day 1, Day 2, Day 3 of cycle 1, Day 8, Day 9, Day 10 of cycle 2.

  3. Area under the plasma concentration versus time curve from 0 to infinity (AUC0-inf)

    90% CI of T/R within 80-125%

    Time frame: Day 1, Day 2, Day 3 of cycle 1, Day 8, Day 9, Day 10 of cycle 2.

06

Study locations

1 site
  • The second hospital of shanxi medical university
    Taiyuan, Shanxi 030001, China
07

Registry details

Key details

Study ID
NCT03424928
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Collaborators
Second Hospital of Shanxi Medical University
Responsible party
Sponsor
First posted
Feb 7, 2018
Start date
Jan 19, 2018
Primary completion
Jan 29, 2018
Completion
Feb 6, 2018
Last update
Feb 7, 2018

Study contacts

Ruigang Hou, Bachelor
principal investigator · Second Hospital of Shanxi Medical University
Linhua Linhua, PhD
principal investigator · Second Hospital of Shanxi Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion